Geron (GERN) Competitors $1.25 -0.07 (-5.30%) Closing price 04:00 PM EasternExtended Trading$1.28 +0.03 (+2.80%) As of 07:08 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock GERN vs. FOLD, LGND, DVAX, MNKD, BCRX, INVA, NVAX, OPK, CLDX, and MYGNShould you be buying Geron stock or one of its competitors? The main competitors of Geron include Amicus Therapeutics (FOLD), Ligand Pharmaceuticals (LGND), Dynavax Technologies (DVAX), MannKind (MNKD), BioCryst Pharmaceuticals (BCRX), Innoviva (INVA), Novavax (NVAX), OPKO Health (OPK), Celldex Therapeutics (CLDX), and Myriad Genetics (MYGN). These companies are all part of the "biotechnology" industry. Geron vs. Amicus Therapeutics Ligand Pharmaceuticals Dynavax Technologies MannKind BioCryst Pharmaceuticals Innoviva Novavax OPKO Health Celldex Therapeutics Myriad Genetics Amicus Therapeutics (NASDAQ:FOLD) and Geron (NASDAQ:GERN) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, media sentiment, risk, dividends, analyst recommendations, earnings, profitability and community ranking. Which has higher valuation and earnings, FOLD or GERN? Amicus Therapeutics has higher revenue and earnings than Geron. Amicus Therapeutics is trading at a lower price-to-earnings ratio than Geron, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAmicus Therapeutics$528.30M4.01-$151.58M-$0.18-38.33Geron$76.99M10.34-$184.13M-$0.27-4.63 Is FOLD or GERN more profitable? Amicus Therapeutics has a net margin of -10.62% compared to Geron's net margin of -682.48%. Amicus Therapeutics' return on equity of 12.44% beat Geron's return on equity.Company Net Margins Return on Equity Return on Assets Amicus Therapeutics-10.62% 12.44% 2.60% Geron -682.48%-67.53%-45.46% Does the media favor FOLD or GERN? In the previous week, Geron had 24 more articles in the media than Amicus Therapeutics. MarketBeat recorded 34 mentions for Geron and 10 mentions for Amicus Therapeutics. Amicus Therapeutics' average media sentiment score of 1.00 beat Geron's score of 0.05 indicating that Amicus Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amicus Therapeutics 6 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Geron 3 Very Positive mention(s) 3 Positive mention(s) 21 Neutral mention(s) 3 Negative mention(s) 2 Very Negative mention(s) Neutral Which has more risk and volatility, FOLD or GERN? Amicus Therapeutics has a beta of 0.79, meaning that its share price is 21% less volatile than the S&P 500. Comparatively, Geron has a beta of 0.66, meaning that its share price is 34% less volatile than the S&P 500. Does the MarketBeat Community favor FOLD or GERN? Amicus Therapeutics received 32 more outperform votes than Geron when rated by MarketBeat users. Likewise, 72.98% of users gave Amicus Therapeutics an outperform vote while only 70.03% of users gave Geron an outperform vote. CompanyUnderperformOutperformAmicus TherapeuticsOutperform Votes53272.98% Underperform Votes19727.02% GeronOutperform Votes50070.03% Underperform Votes21429.97% Do analysts prefer FOLD or GERN? Amicus Therapeutics presently has a consensus price target of $16.75, suggesting a potential upside of 142.75%. Geron has a consensus price target of $5.75, suggesting a potential upside of 360.00%. Given Geron's stronger consensus rating and higher possible upside, analysts plainly believe Geron is more favorable than Amicus Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Amicus Therapeutics 0 Sell rating(s) 2 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.78Geron 0 Sell rating(s) 3 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 2.82 Do institutionals & insiders have more ownership in FOLD or GERN? 73.7% of Geron shares are held by institutional investors. 2.2% of Amicus Therapeutics shares are held by company insiders. Comparatively, 3.1% of Geron shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. SummaryAmicus Therapeutics beats Geron on 10 of the 18 factors compared between the two stocks. Remove Ads Get Geron News Delivered to You Automatically Sign up to receive the latest news and ratings for GERN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GERN vs. The Competition Export to ExcelMetricGeronPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$796.13M$6.32B$5.33B$7.57BDividend YieldN/A3.23%5.11%4.32%P/E Ratio-3.916.7921.7317.81Price / Sales10.34225.93379.1994.60Price / CashN/A65.6738.1534.64Price / Book2.725.866.464.00Net Income-$184.13M$141.86M$3.20B$247.23M7 Day Performance-2.34%8.98%6.54%7.26%1 Month Performance-23.78%-12.65%-8.55%-6.26%1 Year Performance-63.77%-11.99%10.33%-0.18% Geron Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GERNGeron3.7691 of 5 stars$1.25-5.3%$5.75+360.0%-63.7%$796.13M$76.99M-3.9170Short Interest ↑Gap DownFOLDAmicus Therapeutics4.0285 of 5 stars$7.07-5.8%$16.75+137.1%-37.1%$2.18B$528.30M-39.47480Positive NewsGap DownLGNDLigand Pharmaceuticals4.3435 of 5 stars$98.73-0.8%$147.00+48.9%+31.0%$1.91B$167.13M39.5080Analyst UpgradeNews CoveragePositive NewsGap DownDVAXDynavax Technologies4.3787 of 5 stars$12.44-1.6%$21.50+72.8%-3.4%$1.54B$277.25M69.18350Positive NewsGap DownMNKDMannKind2.2584 of 5 stars$4.62-2.6%$9.21+99.7%+11.6%$1.41B$285.50M66.36400BCRXBioCryst Pharmaceuticals4.1287 of 5 stars$6.64-2.9%$15.57+134.7%+47.6%$1.39B$450.71M-10.93530Gap DownINVAInnoviva4.3495 of 5 stars$17.43-1.6%$55.00+215.5%+22.9%$1.09B$358.71M25.29100Analyst UpgradeNews CoveragePositive NewsNVAXNovavax3.6164 of 5 stars$6.39+2.4%$18.00+181.8%+49.8%$1.04B$682.16M-2.861,990OPKOPKO Health4.1159 of 5 stars$1.53-1.6%$2.75+80.3%+15.4%$1.03B$713.14M-8.083,930Options VolumeCLDXCelldex Therapeutics2.3254 of 5 stars$15.28-3.2%$54.33+255.6%-54.7%$1.02B$7.02M-5.95150Positive NewsMYGNMyriad Genetics3.823 of 5 stars$8.01-1.5%$20.89+160.9%-58.7%$729.56M$837.60M-6.152,700Gap Down Remove Ads Related Companies and Tools Related Companies FOLD Competitors LGND Competitors DVAX Competitors MNKD Competitors BCRX Competitors INVA Competitors NVAX Competitors OPK Competitors CLDX Competitors MYGN Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GERN) was last updated on 4/15/2025 by MarketBeat.com Staff From Our Partners[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Geron Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Geron With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy GERN Stock Free GERN Stock Alerts